Howes JF - Search Results

1

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.

Mash DC, Ameer B, Prou D, Howes JF, Maillet EL. Mash DC, et al. Among authors: howes jf. J Psychopharmacol. 2016 Jul;30(7):688-97. doi: 10.1177/0269881116641331. Epub 2016 Apr 4. J Psychopharmacol. 2016. PMID: 27044509

2

Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients.

Glue P, Cape G, Tunnicliff D, Lockhart M, Lam F, Hung N, Hung CT, Harland S, Devane J, Crockett RS, Howes J, Darpo B, Zhou M, Weis H, Friedhoff L. Glue P, et al. Clin Pharmacol Drug Dev. 2016 Nov;5(6):460-468. doi: 10.1002/cpdd.254. Epub 2016 Apr 1. Clin Pharmacol Drug Dev. 2016. PMID: 27870477 Clinical Trial.

3

Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics.

Glue P, Cape G, Tunnicliff D, Lockhart M, Lam F, Gray A, Hung N, Hung CT, Harland S, Devane J, Howes J, Weis H, Friedhoff L. Glue P, et al. J Clin Pharmacol. 2016 Aug;56(8):960-5. doi: 10.1002/jcph.704. Epub 2016 Feb 29. J Clin Pharmacol. 2016. PMID: 26763764 Clinical Trial.

4

Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist.

Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, Weidler D. Dixon R, et al. J Clin Pharmacol. 1987 Mar;27(3):233-9. doi: 10.1002/j.1552-4604.1987.tb02191.x. J Clin Pharmacol. 1987. PMID: 3680580 Clinical Trial.

5

Nalmefene: intravenous safety and kinetics of a new opioid antagonist.

Dixon R, Howes J, Gentile J, Hsu HB, Hsiao J, Garg D, Weidler D, Meyer M, Tuttle R. Dixon R, et al. Clin Pharmacol Ther. 1986 Jan;39(1):49-53. doi: 10.1038/clpt.1986.9. Clin Pharmacol Ther. 1986. PMID: 3943269 Clinical Trial.

6

Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.

Buchwald P, Juhász A, Bell C, Pátfalusi M, Howes J, Bodor N. Buchwald P, et al. J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):377-400. doi: 10.1007/s10928-005-0001-y. J Pharmacokinet Pharmacodyn. 2005. PMID: 16320099 Clinical Trial.

7

Influence of the N-acetylation polymorphism on the metabolism of talampanel: an investigation in fasted and fed subjects genotyped for NAT2 variants.

Buchwald P, Juhász A, Bell C, Pátfalusi M, Kovács P, Hochhaus G, Howes J, Bodor N. Buchwald P, et al. Pharmazie. 2006 Feb;61(2):125-34. Pharmazie. 2006. PMID: 16526560 Clinical Trial.

8

Talampanel.

Howes JF, Bell C. Howes JF, et al. Neurotherapeutics. 2007 Jan;4(1):126-9. doi: 10.1016/j.nurt.2006.11.001. Neurotherapeutics. 2007. PMID: 17199027 Free PMC article. Review.

9

28-day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period.

Miklós A, Magyar Z, Kiss E, Novák I, Grósz M, Nyitray M, Dereszlay I, Czégeni E, Druga A, Howes J, Bodor N. Miklós A, et al. Pharmazie. 2002 Feb;57(2):142-6. Pharmazie. 2002. PMID: 11878192

10

The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.

Wu WM, Bodor ET, Howes J, Bodor N. Wu WM, et al. Pharmazie. 2012 May;67(5):406-10. Pharmazie. 2012. PMID: 22764572

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters